Browse

Major Medicare Advantage plans almost always reversed their denials on appeal, raising big questions about barriers to care.

<p>The data showed that del-brax, an “antisense oligonucleotide conjugate” being tested against a muscle-wasting disease, met its primary endpoint in a Phase 1/2 study.</p>

Seniors' drug costs rise sharply, Enliven's leukemia drugs, and more biotech news from The Readout